Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odronextamab + CHOP vs Rituximab + CHOP in Previously Untreated DLBCL
NCT06091865Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2023
- Primary completion
- Mar 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of odronextamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Regeneron Pharmaceuticals. Started Dec 2023; status: recruiting.
02
Drugs
odronextamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06091865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06091865.